Compare iShares Core MSCI EAFE ETF (IEFA) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Mesoblast Limited — how do they compare? iShares Core MSCI EAFE ETF trades at $96.2 (market cap $189.19B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 108.1× Mesoblast Limited's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Mesoblast Limited for 14 Days on average.
| IEFA | MESO | |
|---|---|---|
Market Cap | $189.19B | $1.75B |
Volume | 8,441,787 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $20.96 |
52-Week Low | $85.06 | $13.19 |
Typical Hold Time | 41 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with a bearish technical signal. The ETF manages $196 billion in assets, focusing on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors but lower recent performance than some peers. Technical indicators show oversold conditions with RSI at 28.63, while moving averages remain bearish with key support at $95.
The outlook remains cautious given bearish technical momentum and competitive pressure from lower-cost alternatives. International diversification benefits are offset by underperformance relative to global and emerging market ETFs. Key risks include currency fluctuations and concentrated U.S. market exposure driving defensive shifts.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
